Characteristics of cultured human melanocytes from different stages of tumor progression

  • Ulrich Rodeck
  • Meenhard Herlyn
Part of the Cancer Treatment and Research book series (CTAR, volume 43)

Abstract

Early studies on chemically induced carcinomas in animals suggested that tumorigenesis is not a one-step phenomenon but rather represents a sequence of events leading to increasingly aggressive neoplasms [1, 2]. The concept of distinct sequential stages in the development of malignant cells has gained wide acceptance for both experimentally induced and sporadic malignancies [3].

Keywords

Agarose Propa Oncol Polypeptide Plasminogen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Foulds L: Mammary tumours in hybrid mice: Growth and progression of spontaneous tumors. Br J Cancer 3:345–375, 1949.PubMedCrossRefGoogle Scholar
  2. 2.
    Foulds L: Neoplastic development, vol. I. New York: Academic Press, 1969, pp. 69–75.Google Scholar
  3. 3.
    Farber E, Cameron, R: The sequential analysis of cancer development. In: Advances in cancer research, vol. 31. New York: Academic Press, 1980, pp. 125–226.CrossRefGoogle Scholar
  4. 4.
    Clark WH, Elder DE, Guerry D, Epstein MN, Greene MH, Van Horn M: A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Human Pathol 15:1147–1165, 1984.CrossRefGoogle Scholar
  5. 5.
    Elder DE, Clark WH: Developmental biology of malignant melanoma. In: Pigment cell, vol. 8. Karger Basel, 1987, pp. 1–28.Google Scholar
  6. 6.
    Clark WH, Elder DE, Van Horn M: The biologic forms of malignant melanoma. Human Pathol 17:443–450, 1986.CrossRefGoogle Scholar
  7. 7.
    Herlyn M, Herlyn D, Elder DE, Bondi E, LaRossa D, Hamilton R, Sears H, Balaban G, Guerry D, Clark WH, Koprowski H: Phenotypic characteristics of cells derived from precursors of human melanoma. Cancer Res 43:5502–5508, 1983.PubMedGoogle Scholar
  8. 8.
    Herlyn M, Thurin J, Balaban G, Bennicelli J, Herlyn D, Elder DE, Bondi E, Guerry D, Nowell P, Clark WH, Koprowski H: Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 45:5670–5676, 1985.PubMedGoogle Scholar
  9. 9.
    Eisinger M, Marko O, Ogata S-I, Old LJ: Growth regulation of human melanocytes: Mitogenic factors in extracts of melanoma, astrocytoma, and fibroblast cell lines. Science 229:984–986, 1985.PubMedCrossRefGoogle Scholar
  10. 10.
    Halaban R, Ghosh S, Duray P, Kirkwood JM, Lerner AB: Human melanocytes cultured from nevi and melanomas. J Invest Dermatol 87:95–101, 1986.PubMedCrossRefGoogle Scholar
  11. 11.
    Gilchrest BA, Treloar V, Grassi AM, Yaar M, Szabo G, Flynn E: Characteristics of cultivated adult human nevocellular nevus cells. J Invest Dermatol 87:102–107, 1986.PubMedCrossRefGoogle Scholar
  12. 12.
    Mancianti ML, Herlyn M, Weil D, Jambrosic J, Rodeck U, Becker D, Diamond L, Clark WH, Koprowski H: Growth and phenotypic characteristics of human nevus cells in culture. J Invest Dermatol 90:134–141, 1988.PubMedCrossRefGoogle Scholar
  13. 13.
    Herlyn M, Rodeck U, Mancianti ML, Cardillo F, Lang A, Ross A, Jambrosic J, Koprowski H: Expression of melanoma-associated antigens in rapidly dividing human melanocytes. Cancer Res 47:3057–3061, 1987.PubMedGoogle Scholar
  14. 14.
    Halaban R, Alfano FD: Selective elimination of fibroblasts from cultures of normal human melanocytes. In Vitro 20:447–450, 1984.PubMedCrossRefGoogle Scholar
  15. 15.
    Rodeck U, Herlyn M, Menssen H, Furlanetto RW, Koprowski H: Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer 40:687–690, 1987.PubMedCrossRefGoogle Scholar
  16. 16.
    Eisinger M, Marko O: Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci USA 79:2018–2022, 1982.PubMedCrossRefGoogle Scholar
  17. 17.
    Halaban R, Ghosh S, Baird A: bFGF is the putative natural growth factor for human melanocytes. In Vitro 23:47–52, 1987.Google Scholar
  18. 18.
    Wilkins L, Gilchrest GA, Szabo G, Weinstein R, Maciag T: The stimulation of normal human melanocyte proliferation in vitro by melanocyte growth factor from bovine brain. J Cell Physiol 122:350–361, 1985.PubMedCrossRefGoogle Scholar
  19. 19.
    Richmond A, Fine R, Murray D, Lawson DH, Priest JH: Growth factor and cytogenic abnormalities in cultured nevi and malignant melanomas. J Invest Dermatol 86:295–302, 1986.PubMedCrossRefGoogle Scholar
  20. 20.
    Sporn MB, Roberts AB: Autocrine growth factors and cancer. Nature 313:745–747, 1985.PubMedCrossRefGoogle Scholar
  21. 21.
    Heldin C-H, Westermark B: Growth factors: Mechanism of action and relation to oncogenes. Cell 37:9–20, 1984.PubMedCrossRefGoogle Scholar
  22. 22.
    Holley RW: Control of growth of mammalian cells in culture. Nature 258:487–490, 1975.PubMedCrossRefGoogle Scholar
  23. 23.
    Marquardt H, Todaro G: Human transforming growth factor—production by a melanoma cell line, purification, and initial characterization. J Biol Chem 257:5220–5227, 1982.PubMedGoogle Scholar
  24. 24.
    Richmond A, Lawson DH, Nixon DW, Stedman NJ, Stevens S, Chawla RK: Extraction of a melanoma growth-stimulatory activity from culture medium conditioned by the Hs0294 human melanoma cell line. Cancer Res 43:2106–2112, 1983.PubMedGoogle Scholar
  25. 25.
    Richmond A, Lawson DH, Nixon DW, Chawla RK: Characterization of autostimulatory and transforming growth factors from human melanoma cells. Cancer Res 45:6390–6394, 1985.PubMedGoogle Scholar
  26. 26.
    DeLarco JE, Pigott DA, Lazarus JA: Ectopic peptides released by a human melanoma cell line that modulate the transformed phenotype. Proc Natl Acad Sci USA 82:5015–5019, 1985.CrossRefGoogle Scholar
  27. 27.
    Kim MK, Warren TC, Kimball ES: Purification and characterization of a low molecular weight transforming growth factor from the urine of melanoma patients. J Biol Chem 260:9237–9243, 1985.PubMedGoogle Scholar
  28. 28.
    Westermark B, Johnsson A, Paulsson Y, Betsholtz C, Heldin C-H, Herlyn M, Rodeck U, Koprowski H: Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci USA 83:7197–7200, 1986.PubMedCrossRefGoogle Scholar
  29. 29.
    Moscatelli D, Presta M, Joseph-Silverstein J, Rifkin D: Both normal and tumor cells produce basic fibroblast growth factor. J Cell Physiol 129:273–276, 1986.PubMedCrossRefGoogle Scholar
  30. 30.
    Ogata S, Furuhashi Y, Eisinger M: Growth stimulation of human melanocytes: Identification and characterization of melanoma-derived melanocyte growth factor. Biochem Biophys Res Commun 146:1204–1211, 1987.PubMedCrossRefGoogle Scholar
  31. 31.
    Fidler IJ, Hart IR: Biological diversity in metastatic neoplasms: Origins and implications. Science (Washington, DC) 217:998–1003, 1982.PubMedCrossRefGoogle Scholar
  32. 32.
    Nicolson GL, Milas L (eds): Cancer invasion and metastasis. Biological and therapeutic aspects. New York: Raven Press, 1984.Google Scholar
  33. 33.
    Liotta LA, Hart IR (eds): Tumor invasion and metastasis. The Hague, Boston: Martinus Nijhoff, 1982.Google Scholar
  34. 34.
    Herlyn M, Koprowski H. Melanoma antigens: Immunological and biological characterization and clinical significance. Ann Rev Immunol 6:283–308, 1988.CrossRefGoogle Scholar
  35. 35.
    Matyas GR, Evers DC, Radinsky R, Morre DJ: Fibronectin binding to gangliosides and rat liver plasma membranes. Exp Cell Res 162:296–318, 1986.PubMedCrossRefGoogle Scholar
  36. 36.
    Cheresh DA, Klier FG: Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. J Cell Biol 102:1887–1897, 1986.PubMedCrossRefGoogle Scholar
  37. 37.
    Cheresh DA, Harper JR, Schulz G, Reisfeld RA: Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81:5767–5771, 1984.PubMedCrossRefGoogle Scholar
  38. 38.
    Rosenberg JM, Reisfeld RA, Sander DJ, Cheresh DA: A specific sialyltransferase is responsible for the synthesis of GD3, a ganglioside preferentially expressed on human metastatic melanoma cells. Proc Am Assoc Cancer Res 27:1, 1986.Google Scholar
  39. 39.
    Thurin J, Thurin M, Herlyn M, Elder DE, Steplewski Z, Clark WH, Koprowski H: GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lett 208:17–22, 1986.PubMedCrossRefGoogle Scholar
  40. 40.
    Dippold WG, Knuth A, Meyer zum Büschenfelde K-H: Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res 44:806–810, 1984.PubMedGoogle Scholar
  41. 41.
    Iliopoulos D, Ernst C, Steplewski Z, Jambrosic JA, Rodeck U, Herlyn M, Clark WH, Koprowski H, Herlyn D: Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. Submitted.Google Scholar
  42. 42.
    Garbisa S, Pozatti R, Muschel R, Libbey NP, Spremulli EN, Calabresi P: Secretion of type IV collagenolytic protease and metastatic phenotype: Induction by transfection with c-Ha-ras but not c-Haras plus Ad2-Ela. Cancer Res 47:1523–1528, 1987.PubMedGoogle Scholar
  43. 43.
    Duffi MJ, O’Grady PO: Plasminogen activator and cancer. Eur J Cancer Clin Oncol 20:577–582, 1984.CrossRefGoogle Scholar
  44. 44.
    Cajot J, Kruithof EKO, Schleuning W-D, Sordat B, Bachmann F: Plasminogen activator, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer 38:719–727, 1986.PubMedCrossRefGoogle Scholar
  45. 45.
    Salo T, Liotta LA, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K: Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells-role in metastasis. Int J Cancer 30:669–673, 1982.PubMedCrossRefGoogle Scholar
  46. 46.
    Turpeenniemi-Hujanen T, Thorgeirson UP, Hart IP, Grant SS, Liotta LA: Expression of collagenase type IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst 75:99–103, 1985.PubMedGoogle Scholar
  47. 47.
    Koprowski H, Steplewski Z, Herlyn D, Herlyn M: Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci USA 75:3405–3409, 1978.PubMedCrossRefGoogle Scholar
  48. 48.
    Reisfeld RA, Cheresh DA: Human tumor antigens. Adv Immunol 40:323–377, 1987.PubMedCrossRefGoogle Scholar
  49. 49.
    Bumol TF, Reisfeld RA: Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci USA 79:1245–1249, 1982.PubMedCrossRefGoogle Scholar
  50. 50.
    de Vries JE, Keizer GD, teVelde AA, Voordouw A, Ruiter D, Rumke P, Spits H, Figdor CG: Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. Int J Cancer 38:465–473, 1986.PubMedCrossRefGoogle Scholar
  51. 51.
    Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ: GD3—a prominent ganglioside of human melanoma: Detection and characterization by mouse monoclonal antibody. J Exp Med 155:1133–1147, 1982.PubMedCrossRefGoogle Scholar
  52. 52.
    Natali PG, Nicotra MR, Belocci M, Cavaliere R, Bigotti A: Distribution of laminin and collagen type-IV in benign and malignant lesions of melanocyte origin. Int J Cancer 35: 461–467, 1985.PubMedCrossRefGoogle Scholar
  53. 53.
    Brown JP, Woodbury RR, Hart CE, Hellstrom I, Hellstrom KE: Structural characterization of human melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci USA 78:539–545, 1980.CrossRefGoogle Scholar
  54. 54.
    Weiss SW, Langloss JM, Enzinger FM: Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest 49:299–308, 1983.PubMedGoogle Scholar
  55. 55.
    Ross AH, Grob P, Bothwell MA, Elder DE, Ernst CS, Marano N, Ghrist BFD, Stemp CC, Herlyn M, Atkinson B, Koprowski H: Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci USA 81:6681–6685, 1984.PubMedCrossRefGoogle Scholar
  56. 56.
    Koprowski H, Herlyn M, Balaban G, Parmiter A, Ross AH, Nowell PC: Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet 1:297–302, 1985.CrossRefGoogle Scholar
  57. 57.
    Thomson TM, Mattes M, Ranx L, Old LJ, Lloyd KO: Pigmentation-associated glycoprotein of human melanomas and melanocytes: Definition with a mouse monoclonal antibody. J Invest Dermatol 85:169–174, 1985.PubMedCrossRefGoogle Scholar
  58. 58.
    Hayashibe K, Mishima Y, Ichihashi M, Kawai M: Melanosomal antigenic expression on the cell surface and intra-cellular subunits within melanogenic compartments of pigment cells: Analysis by anti-melanosome-associated monoclonal antibody. J Invest Dermatol 87:89–94, 1986.PubMedCrossRefGoogle Scholar
  59. 59.
    Winchester RG, Wang C-Y, Gibofsky A, Kunkle HG, Lloyd KO, Old LJ: Expression of la-like antigens on cultured malignant melanoma cell lines. Proc Natl Acad Sci USA 75:6235–6239, 1978.PubMedCrossRefGoogle Scholar
  60. 60.
    Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H: Biology of tumor progression in human melanocytes. Lab Invest 56:461–474, 1987.PubMedGoogle Scholar
  61. 61.
    Gaynor R, Irie R, Morton D, Herschmann HR: S-100 protein is present in cultured human malignant melanomas. Nature 286:400–401, 1980.PubMedCrossRefGoogle Scholar
  62. 62.
    Ross AH, Herlyn M, Maul GH, Koprowski H, Bothwell M, Chao M, Pleasure D, Sonnenfeld KH: The nerve growth factor receptor in normal and transformed neural crest cells. Ann NY Acad Sci 486:115–123, 1986.PubMedCrossRefGoogle Scholar
  63. 63.
    Rodeck U, Herlyn M, Koprowski H: Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem 35:315–320, 1987.PubMedCrossRefGoogle Scholar
  64. 64.
    Guerry D, Alexander MA, Herlyn M, Zehngebot LM, Mitchell KF, Zmijewski CM, Lusk EJ: HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest 73:267–271, 1984.PubMedCrossRefGoogle Scholar
  65. 65.
    Fossati G, Taramelli D, Dalsari A, Bogdanovich G, Andreola S, Parmiani G: Primary but not metastatic human melanoma expressing DR antigens stimulate autologous lymphocytes. Int J Cancer 33:591–597, 1984.PubMedCrossRefGoogle Scholar
  66. 66.
    Houghton AN, Cordon-Cardo C, Eisinger M: Differentiation antigens of melanoma and melanocytes. Int Rev Exp Pathol 28:317–329, 1986.Google Scholar
  67. 67.
    Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ: Surface antigens of melanoma and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of antigenic expression in cultured cells and tissues. Cancer Res 45:4401–4411, 1985.PubMedGoogle Scholar
  68. 68.
    Holzmann B, Bröcker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmüller G, Johnson JP: Tumor progression in human malignant melanoma: Five stages defined by their antigenic phenotype. Int J Cancer 39:466–471, 1987.PubMedCrossRefGoogle Scholar
  69. 69.
    Thompson JJ, Herlyn M, Elder DE, Clark WH, Steplewski Z, Koprowski H: Use of monoclonal antibodies in detection of melanoma-associated antigens in cultured rapidly dividing human melanocytes. Am J Pathol 107:357–361, 1982.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1988

Authors and Affiliations

  • Ulrich Rodeck
  • Meenhard Herlyn

There are no affiliations available

Personalised recommendations